UIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION!
|
|
|
- Geraldine Boyd
- 5 years ago
- Views:
Transcription
1 UIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION! STÉPHANE JOUNEAU 11 JULY 2014 Respiratory Medicine Department, Pontchaillou Hospital, Rennes, France
2 CASE OVERVIEW This case highlights how a usual interstitial pneumonia (UIP) pattern may be caused by a number of different pathologies, not just idiopathic pulmonary fibrosis (IPF). In order to make an accurate diagnosis of IPF, it is important to conduct a rigorous clinical primary examination to exclude other pathophysiological causes 2
3 MEDICAL HISTORY AND TESTS Initial visit (July 2012) Male, 67 years old 90 kg, 175 cm Ex-smoker: 15 pack-years Occupation: Former commercial delegate who travelled regularly to USA, China and North Africa; no history of environmental exposures 3
4 MEDICAL HISTORY AND TESTS Initial visit (July 2012) Comorbidities: Arterial hypertension, type 2 diabetes, coronary heart disease (stent in 2004), mesenteric infarction (1995) and arthrosis Current medications: Esomeprazole 20 mg, ramipril 5 mg, ASA 75 mg, metoprolol 200 mg, metformin 850 mg, gliclazide 60 mg and simvastatin 20 mg 4
5 MEDICAL HISTORY AND TESTS Initial visit (July 2012) Physical examination: Chronic productive cough (with mucopurulent sputum) and mild dyspnoea (New York Heart Association Stage I) but no asthenia, anorexia or fever Patient had a history of recurrent lower respiratory tract infections in the past 2 years Blood pressure 120/60 mmhg Heart rate 56 beats per minute SpO 2 (room air) = 98% Bibasilar crackles on lung auscultation Hypereosinophilia = 1700/mm 3 5
6 IMAGING HRCT scan (August 2012) Pattern recognised: Subpleural, basal predominance Reticular abnormality Honeycombing Absence of features listed as inconsistent with UIP pattern Conclusion = definite UIP pattern 6
7 IMAGING HRCT (IMAGE 1) HRCT (August 2012) Definite UIP pattern with reticular abnormalities with a subpleural, basal predominance (arrows) 7
8 IMAGING HRCT (IMAGE 2) HRCT (August 2012) Honeycombing with a subpleural, basal predominance (circles) 8
9 IMAGING HRCT (IMAGE 3) HRCT (August 2012) Reticular abnormalities (arrows) and honeycombing (circles) with a subpleural, basal predominance 9
10 IMAGING HRCT (IMAGE 4) HRCT (August 2012) Reticular abnormalities (arrows) and honeycombing (circles) 10
11 IMAGING HRCT (IMAGE 5) HRCT (August 2012) Reticular abnormalities (arrows) and honeycombing (circles) 11
12 IMAGING HRCT (IMAGE 6) HRCT (August 2012) Reticular abnormalities (arrows) and honeycombing (circles 12
13 QUESTIONS Image subscript added, we have obtained the permission to use the image Question 1 If a patient with the signs shown in the photo and a definite UIP pattern on chest CT-scan presents at the clinic complaining of bilateral joints and muscles pains, following a recent occurrence of Raynaud syndrome, what is the most probable diagnosis? Idiopathic pulmonary fibrosis Rheumatoid arthritis with ILD Diffuse erythematous lupus with ILD Anti-synthetase syndrome with ILD [correct answer] Jouneau S., et al. Les manifestations pulmonaires du syndrome des antisynthetases. Revue des Maladies Respiratoires, Elsevier Masson, 2014, in press. Used with permission of the Société de Pneumologie de Langue Française. 13
14 ANSWERS Answer 1 Although there is a high variability in symptoms and severity, the presence of a number of extra-thoracic manifestations, such as myalgia or muscular deficit, Raynaud s phenomenon, polyarthritis, fever, or mechanics hands in association with interstitial lung disease are all suggestive of antisynthetase syndrome. 1,2 However, positive anti-rna synthetase antibodies (anti-jo1, anti-pl7, and anti-pl12) are required to confirm the diagnosis. 1,2 1 Solomon J, et al. J Bras Pneumol. 2011;37(1): ; 2 Fischer A, et al. Respir Med. 2009;103(11):
15 LUNG FUNCTION Lung function measurements (August 2012) Overall, lung function/gas exchange appeared to be good There were no signs of infection or connective tissue disease Results of bronchoalveolar lavage appeared normal; however, additional blood tests revealed an increasing eosinophil count A 6-minute walk test was not performed
16 LUNG FUNCTION Lung function measurements (August 2012) Parameter FEV 1 /FVC FEV 1 FVC DLCO Value (% of predicted) 89% predicted 117% predicted 98% predicted 62% predicted 16
17 LABORATORY Laboratory results Blood eosinophil count: 2200/mm 3 in August 2012; 2700/mm 3 in September 2012 Parameter Antinuclear antibody Rheumatoid factor Anti-cyclic citrullinated peptide antibodies Anti-neutrophil cytoplasmic antibodies Results Negative Negative Negative Negative 17
18 BRONCHOSCOPY Bronchoscopy results Normal bronchial tree with no macroscopic anomalies observed BAL differential cell count: Parameter Total cell count Value cells/ml Alveolar macrophages 87% Lymphocytes 12% Neutrophils 1% Eosinophils 0% Ø Normal BAL differential count, no hypereosinophilia on BAL 18
19 QUESTIONS Question 2 What would make you suspect another diagnosis other than IPF? Possible UIP pattern on chest CT-scan Probable UIP pattern on pulmonary histology Numerous long-term medications 42 year-old patient [correct answer] 19
20 ANSWERS Answer 2 Because IPF is rare before the age of 50, the index of suspicion for an underlying connective tissue disease should be high. 1 In such a young patient, you have to be very careful with the diagnosis of IPF. The patient should be promptly referred to a lung transplant centre and evaluated for specific telomerase mutations ie, SFPC, SFPB, GATA Spagnolo P, et al. Multidisciplinary Respiratory Medicine 2012;7:42; 2 Savage S, and Bertuch A. Genetics in Medicine 2010;12:
21 MEDICAL HISTORY AND TESTS Follow-up (July 2013) Similar to on first presentation; however, the patient s dyspnoea had worsened (New York Heart Association Stage II) Laboratory findings were also similar to those observed on initial presentation with the exception of the patient s eosinophil count, which had increased 3500/mm 3 in July /mm 3 in September 2013 Raised suspicion of possible Churg-Strauss syndrome or parasitic infection such as aspergillosis, ascaridosis, lymphatic filariasis, distomatosis, trichinosis, toxocaris, strongyloides Also possibility of other connective tissue diseases e.g. rheumatoid arthritis or systemic lupus erythematosus 21
22 IMAGING HRCT scan (July 2013) Consistent with a definite UIP pattern, including Reticular abnormalities 22
23 IMAGING HRCT (IMAGE 1) HRCT (July 2013) Reticular abnormalities 23
24 IMAGING HRCT (IMAGE 2) HRCT (July 2013) Honeycombing 24
25 IMAGING HRCT (IMAGE 3) HRCT (July 2013) Reticular abnormalities (arrows) and honeycombing (circles 25
26 IMAGING HRCT (IMAGE 4) HRCT (July 2013) Reticular abnormalities (arrows) and honeycombing (circles 26
27 IMAGING HRCT (IMAGE 5) HRCT (July 2013) Reticular abnormalities (arrows) and honeycombing (circles 27
28 IMAGING HRCT (IMAGE 6) HRCT (July 2013) Reticular abnormalities (arrows) and honeycombing (circles 28
29 LUNG FUNCTION Lung function measurements (July 2013) Parameter FEV 1 /FVC FEV 1 FVC TLC DLCO Value (% of predicted) 86% predicted 105% predicted 90% predicted 86% predicted 57% predicted Parameter Value (absolute) ph 7.48 PaO 2 92 mmhg PaCO 2 35 mmhg CO 2 24% SaO 2 97% Slight decline in lung function from previous visit 29
30 LUNG FUNCTION Lung function measurements (July 2013) Results of 6-minute walk test (room air): 480 m without pause, no desaturation (100% à 99%); Borg 2 à 3 30
31 LABORATORY Haematology results (September 2013) To exclude other causes such as Churg Strauss syndrome or parasitic infections a myelogram, osteomedullar biopsy and medullary karyotyping were conducted All tests appeared normal Furthermore, and because there was a suspicion of hypereosinophilic syndrome the patient was genotyped Genotyping identified an FIP1L1-PDGFRα fusion gene 31
32 DIAGNOSIS 1. HRCT scans revealed a UIP pattern suggestive of IPF; however, the patient s lung function remained relatively stable throughout 2. Laboratory tests revealed an increasing eosinophil count 3. Following genotyping an FIP1L1-PDGFRα fusion gene was identified The patient was diagnosed as having either IPF and hypereosinophilic syndrome or hypereosinophilic syndrome with lung fibrosis Imatinib was initiated 32
33 LEARNINGS FROM THE CASE 1. Demonstrates the importance of a thorough clinical examination, including physical examination, laboratory tests and blood work-up, and HRCT in the diagnosis of interstitial lung diseases 2. Highlights that, in complex cases, a pulmonologist must also think like an internist and consider pulmonary manifestations of other diseases 33
Patient with IPF and no honeycombing on HRCT. Case 1 Demosthenes Bouros, Vasilios Tzilas University of Athens
Patient with IPF and no honeycombing on HRCT Case 1 Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 76-year-old male patient presented with progressive exertional dyspnoea refractory
5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective No, I am not a pulmonologist! Radiology Pathology Clinical 1 Everyone needs a CT Confidence in diagnosis Definitive HRCT +
A case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel
A case of a patient with IPF treated with nintedanib Prof. Kreuter and Prof. Heussel Case Overview This case describes the history of a patient with IPF who, at the time of diagnosis, had symptoms typical
DIAGNOSTIC NOTE TEMPLATE
DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the
Differential diagnosis
Differential diagnosis Idiopathic pulmonary fibrosis (IPF) is part of a large family of idiopathic interstitial pneumonias (IIP), one of four subgroups of interstitial lung disease (ILD). Differential
Case Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco
Case Presentations in ILD Harold R. Collard, MD Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Definition/Classification High-resolution CT scan Multidisciplinary
INTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018
INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial
Patient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens
Patient with FVC>90% predicted Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 63-year-old, male patient with progressive exertional dyspnoea lasting for 2 years and dry cough
A Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco
A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Why it is important Definition/Classification
4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs
Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation
11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective Radiology Pathology Clinical 1 Role of HRCT Diagnosis Fibrosis vs. inflammation Next step in management Response to treatment
A Review of Interstitial Lung Diseases
Outline A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Overview of diagnosis in ILD Why it is important Definition/Classification
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than
TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than PAP) BAL is not required as a diagnostic tool in patients
IDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis and Management
IDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis and Management An ATS Pocket Publication This publication was produced in collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. GUIDELINES
ERS 2016 Congress Highlights Interstitial Lung Disease (ILD)
ERS 216 Congress Highlights Interstitial Lung Disease (ILD) London, UK September 3 rd 7 th 216 The 26 th European Respiratory Society International Congress, (ERS) the largest respiratory meeting in the
June 2013 Pulmonary Case of the Month: Diagnosis Makes a Difference. Lewis J. Wesselius, MD 1 Henry D. Tazelaar, MD 2
June 2013 Pulmonary Case of the Month: Diagnosis Makes a Difference Lewis J. Wesselius, MD 1 Henry D. Tazelaar, MD 2 Departments of Pulmonary Medicine 1 and Laboratory Medicine and Pathology 2 Mayo Clinic
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Idiopathic Pulmonary Fibrosis Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Idiopathic Pulmonary Fibrosis (Esbriet /pirfenidone, Ofev /nintedanib)
Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines
Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines Rebecca Keith, MD Assistant Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO Objectives
CTD-related Lung Disease
13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of
Disclosures. Clinical Approach: Evaluating CTD-ILD for the pulmonologist. ILD in CTD. connective tissue disease or collagen vascular disease
Disclosures Clinical Approach: Evaluating CTD-ILD for the pulmonologist Industry relationships: Actelion, atyr Pharma, Boehringer-Ingelheim, Genentech- Roche, Gilead Aryeh Fischer, MD Associate Professor
COI: no conflicts of interest to declare
Idiopathic versus secondary Usual Interstitial Pneumonia (UIP) pattern in a series of 96 consecutive surgical lung biopsies: The value of histologic ancillary findings in a multidisciplinary discussion
Initial presentation of idiopathic pulmonary fibrosis as an acute exacerbation
Respiratory Medicine CME (2008) 1, 43 47 respiratory MEDICINE CME CASE REPORT Initial presentation of idiopathic pulmonary fibrosis as an acute exacerbation Krishna M. Sundar a,b,, Dixie L. Harris a a
Outline Definition of Terms: Lexicon. Traction Bronchiectasis
HRCT OF IDIOPATHIC INTERSTITIAL PNEUMONIAS Disclosures Genentech, Inc. Speakers Bureau Tadashi Allen, MD University of Minnesota Assistant Professor Diagnostic Radiology 10/29/2016 Outline Definition of
International consensus statement on idiopathic pulmonary fibrosis
Eur Respir J 2001; 17: 163 167 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 PERSPECTIVE International consensus statement on idiopathic
The Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page
The Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page 1135-1140 Role of High Resolution Computed Tomography in Diagnosis of Interstitial Lung Diseases in Patients with Collagen Diseases
New respiratory symptoms and lung imaging findings in a woman with polymyositis
Maria Bolaki 1, Konstantinos Karagiannis 1, George Bertsias 2, Ioanna Mitrouska 1, Nikolaos Tzanakis 1, Katerina M. Antoniou 1 kantoniou@uoc.gr 1 Dept of Thoracic Medicine, Heraklion University Hospital,
Diagnostic challenges in IPF
Medicine, Nursing and Health Sciences Diagnostic challenges in IPF Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University March 2015 Disclosures Consultancy fees from
Myositis and Your Lungs
Myositis and Your Lungs 2013 TMA Annual Patient Meeting Louisville, Kentucky Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Myositis Heterogeneous group of autoimmune syndromes
IPF: Epidemiologia e stato dell arte
IPF: Epidemiologia e stato dell arte Clinical Classification Diffuse parenchimal lung diseases Exposure-related: - occupational - environmental - medication Desquamative interstitial pneumonia Idiopathic
Non-neoplastic Lung Disease II
Pathobasic Non-neoplastic Lung Disease II Spasenija Savic Prince Pathology Program Systematic approach to surgical lung biopsies with ILD Examples (chronic ILD): Idiopathic interstitial pneumonias: UIP,
BRONCHOALVEOLAR LAVAGE (BAL) Venerino Poletti Osp GB Morgagni, Forlì (I)
BRONCHOALVEOLAR LAVAGE (BAL) Venerino Poletti Osp GB Morgagni, Forlì (I) BAL-OTELLI Typical microliths (calcospherites) Acute Respiratory Failure. Clinical history. Treated for GI cancer Bollèe G, et
Financial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature
Financial disclosure I have no financial relationships to disclose. Douglas Johnson D.O. Cardiothoracic Imaging Gaston Radiology COMMON DIAGNOSES IN HRCT High Res Chest Anatomy Nomenclature HRCT Sampling
Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment
Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,
Summary: Key Learning Points, Clinical Strategies, and Future Directions
Summary: Key Learning Points, Clinical Strategies, and Future Directions Introduction Idiopathic pulmonary fibrosis (IPF), a peripheral lobular fibrosis of unknown cause, is a chronic, progressive lung
INTERSTITIAL LUNG DISEASE Dr. Zulqarnain Ashraf
Indep Rev Jul-Dec 2018;20(7-12) Dr. Zulqarnain Ashraf IR-653 Abstract: ILD is a group of diseases affect interstitium of the lung. Repeated insult to the lung cause the interstitium to be damaged. Similarly
Current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis in Europe: the AIR survey
REVIEW IDIOPATHIC PULMONARY FIBROSIS Current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis in Europe: the AIR survey Vincent Cottin 1,2 Affiliations: 1 Hospices Civils de Lyon,
Interstitial Lung Disease
Interstitial Lung Disease Interstitial lung disease (ILD) is a broad category of lung diseases that includes more than 130 disorders which are characterized by scarring (i.e. fibrosis ) and/or inflammation
Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy
Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Jeff Swigris, DO, MS Director, ILD Program National Jewish Health Disclosures Speaker - Boehringer Ingelheim and Genentech Objectives Describe
IPF - Inquadramento clinico
IPF - Inquadramento clinico Sergio Harari Unità Operativa di Pneumologia UTIR Servizio di Fisiopat. Resp. e Emodinamica Polmonare Ospedale S. Giuseppe, Milano Clinical Classification Diffuse parenchimal
Diffuse Interstitial Lung Diseases: Is There Really Anything New?
: Is There Really Anything New? Sujal R. Desai, MBBS, MD ESTI SPEAKER SUNDAY Society of Thoracic Radiology San Antonio, Texas March 2014 Diffuse Interstitial Lung Disease The State of Play DILDs Is There
INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF)
INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF) Marilyn K. Glassberg Csete, M.D. Professor of Medicine, Surgery, and Pediatrics Director, Interstitial and Rare Lung Disease Program
Lines and crackles. Making sense of ILD
Lines and crackles Making sense of ILD Case JM 65 year old male Gradual shortness of breath, going on over a year Some dry cough Ex-smoker, quit 10 years ago Crackles in the bases CXR presented Sent to
Eosinophils and effusion: a clinical conundrum
Ruth Sobala, Kevin Conroy, Hilary Tedd, Salem Elarbi kevin.peter.conroy@gmail.com Respiratory Dept, Queen Elizabeth Hospital, Gateshead, UK. Eosinophils and effusion: a clinical conundrum Case report A
Annual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies A Rheumatologist s Approach to Interstitial Lung Disease Outline ILD classification and patterns in CTD The clinical landscape and
Sarcoidosis Registry Proforma
Patient Demographics Patient Data Has a patient consent form been completed? 1.1 Title Mr 1.2 1.3 Forename(s) PlainText Surname PlainText 1.4 Gender Male 1.5 1.6 1.7 1.8 1.9 Mrs Ms Miss Dr Other
Ontario s Referral and Listing Criteria for Adult Lung Transplantation
Ontario s Referral and Listing Criteria for Adult Lung Transplantation Version 3.0 Trillium Gift of Life Network Adult Lung Transplantation Referral & Listing Criteria PATIENT REFERRAL CRITERIA: The patient
Update on Therapies for Idiopathic Pulmonary Fibrosis. Outline
Update on Therapies for Idiopathic Pulmonary Fibrosis Paul Wolters Associate Professor University of California, San Francisco Outline Classification of Interstitial lung disease Clinical classification
Idiopathic Pulmonary of Care
Chapter 6.1 Living Medical etextbook A Digital Tool at the Point of Care From Projects In Knowledge Pulmonology Idiopathic Pulmonary Fibrosis @Point of Care IPF Case Study: Typical Presentation, Role of
Bronkhorst colloquium Interstitiële longziekten. Katrien Grünberg, klinisch patholoog
Bronkhorst colloquium 2013-2014 Interstitiële longziekten De pathologie achter de CT Katrien Grünberg, klinisch patholoog K.grunberg@vumc.nl Preparing: introduction and 3 cases The introduction on microscopic
Bronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy
Idiopathic Pulmonary Fibrosis Bronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy JMAJ 46(11): 469 474, 2003 Yukihiko SUGIYAMA Professor, Division of Pulmonary Medicine, Department of
PL-7 and Anti-Jo-1 Antibodies. publication is available at link.sp
NAOSITE: Nagasaki University's Ac Title Author(s) Comparison of Pulmonary Involvement PL-7 and Anti-Jo-1 Antibodies Tomonaga, Masaomi; Sakamoto, Noriho Tomoyuki; Harada, Tatsuhiko; Nakash Shintaro; Horai,
Interstitial Lung Diseases(ILD) By : Dr. Shaher M. Samrah Done by : Ibrahim M. sun
Interstitial Lung Diseases(ILD) By : Dr. Shaher M. Samrah Done by : Ibrahim M. sun. 26.11.11 Introduction Interstitial Lung Diseases (ILD) are group of diseases that affect the interstitium of the lungs,
An earlier and more confident diagnosis of idiopathic pulmonary fibrosis
Eur Respir Rev 2012; 21: 124, 141 146 DOI: 10.1183/09059180.00000812 CopyrightßERS 2012 REVIEW: IPF An earlier and more confident diagnosis of idiopathic pulmonary fibrosis Roland M. du Bois ABSTRACT:
SCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW
SCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW Lung disease can be a serious complication of scleroderma. The two most common types of lung disease in patients with scleroderma are interstitial
Scholars Journal of Medical Case Reports
Scholars Journal of Medical Case Reports Sch J Med Case Rep 2015; 3(9B):928-932 Scholars Academic and Scientific Publishers (SAS Publishers) (An International Publisher for Academic and Scientific Resources)
Eosinophilic lung diseases
Eosinophilic lung diseases Chai Gin Tsen Department of Respiratory and Critical Care Medicine Tan Tock Seng Hospital The eyes do not see what the mind does not know Not very common A high index of suspicion
Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment
REVIEW IDIOPATHIC PULMONARY FIBROSIS Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment Vincent Cottin 1,2 and Luca Richeldi 3,4 Affiliations: 1 Hospices
Case 1 : Question. 1.1 What is the intralobular distribution? 1. Centrilobular 2. Perilymphatic 3. Random
Interesting case Case 1 Case 1 : Question 1.1 What is the intralobular distribution? 1. Centrilobular 2. Perilymphatic 3. Random Case 1: Answer 1.1 What is the intralobular distribution? 1. Centrilobular
Changes in HRCT findings in patients with respiratory bronchiolitis-associated interstitial lung disease after smoking cessation
Eur Respir J 2007; 29: 453 461 DOI: 10.1183/09031936.00015506 CopyrightßERS Journals Ltd 2007 Changes in HRCT findings in patients with respiratory bronchiolitis-associated interstitial lung disease after
11/19/2012. The spectrum of pulmonary diseases in HIV-infected persons is broad.
The spectrum of pulmonary diseases in HIV-infected persons is broad. HIV-associated Opportunistic infections Neoplasms Miscellaneous conditions Non HIV-associated Antiretroviral therapy (ART)-associated
Guidelines for Diagnosis and Treatment of IPF
Guidelines for Diagnosis and Treatment of IPF Katerina Antoniou, MD, PhD Lecturer in Thoracic Medicine ERS ILD Group Secretary Medical School, University of Crete Classification of Interstitial Lung Disease
Interstitial Lung Disease (ILD)
Interstitial Lung Disease (ILD) ILD comprises more than 130 distinct disorders Characterized by cellular proliferation, cellular infiltration, and/or fibrosis of the lung parenchyma not due to infection
Combined Pulmonary Fibrosis and Emphysema - A Case Series
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 1 Ver. III (January. 2017), PP 15-19 www.iosrjournals.org Combined Pulmonary Fibrosis and Emphysema
Systemic lupus erythematosus (SLE): Pleuropulmonary Manifestations
08/30/10 09/26/10 Systemic lupus erythematosus (SLE): Pleuropulmonary Manifestations Camila Downey S. Universidad de Chile, School of Medicine, Year VII Harvard University, School of Medicine Sept 17,
C h a p t e r 1 3 Interstitial Lung Disease
C h a p t e r 1 3 Interstitial Lung Disease Shirish P Shah 1, Somesh Chaudhary 2, P Shetty 2 1 Consultant Chest Physician, Nanavati Hospital, Mumbai, Former Head of Department of Chest Medicine, BYL Nair
Manish Powari Regional Training Day 10/12/2014
Manish Powari Regional Training Day 10/12/2014 Large number of different types of Interstitial Lung Disease (ILD). Most are very rare Most patients present with one of a smaller number of commoner diseases
The connective tissue disorders (CTDs), also. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement
Eur Respir J 2009; 33: 882 896 DOI: 10.1183/09031936.00152607 CopyrightßERS Journals Ltd 2009 REVIEW Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement
Case 1. Case Presentation. Disclosure Statement. ILD: What the generalist needs to know
Disclosure Statement Interstitial Lung Disease: What the Generalist Needs to Know A Case Based Approach Talmadge E. King, Jr., M.D. Julius R. Krevans Distinguished Professorship in Internal Medicine Chair,
Interstitial Lung Disease ILD: Definition
Interstitial Lung Disease 2007 Paul F. Simonelli,, MD, PhD, FCCP Clinical Director Center for Interstitial Lung Disease Columbia University Medical Center 1. ILD is not one disorder ILD: Definition 2.
Progress in Idiopathic Pulmonary Fibrosis
Progress in Idiopathic Pulmonary Fibrosis David A. Lynch, MB Disclosures Progress in Idiopathic Pulmonary Fibrosis David A Lynch, MB Consultant: t Research support: Perceptive Imaging Boehringer Ingelheim
Accurate Diagnosis Of Postoperative Pneumonia Requires Objective Data
Accurate Diagnosis Of Postoperative Pneumonia Requires Objective Data David Ebler, MD David Skarupa, MD Andrew J. Kerwin, MD, FACS Jhun de Villa, MD Michael S. Nussbaum, MD, FACS J.J. Tepas III, MD, FACS
Combined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases
CASE REPORT Combined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases Nobuhiko Nagata 1, Kentaro Watanabe 2, Michihiro Yoshimi 3, Hiroshi Okabayashi 4, Katsuo Sueishi 5, Kentaro
Eosinophilic lung diseases - what the radiologist needs to know
Eosinophilic lung diseases - what the radiologist needs to know Poster No.: C-0803 Congress: ECR 2014 Type: Authors: Keywords: DOI: Educational Exhibit E.-M. Heursen, R. Reina Cubero, F. Japon Sola; Cádiz/ES
SESSION IV: MECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS PULMONARY PATHOLOGY I. December 5, 2012
SESSION IV: MECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS PULMONARY PATHOLOGY I December 5, 2012 FACULTY COPY GOAL: Describe the basic morphologic and pathophysiologic changes in various conditions
Usual Interstitial pneumonia and Nonspecific Interstitial Pneumonia. Nitra and the Gangs.
Usual Interstitial pneumonia and Nonspecific Interstitial Pneumonia Nitra and the Gangs. บทน ำและบทท ๓, ๑๐, ๑๒, ๑๓, ๑๔, ๑๕, ๑๗ Usual Interstitial Pneumonia (UIP) Most common & basic pathologic pattern
Management of idiopathic pulmonary fibrosis: selected case reports
CASE-BASED REVIEW IDIOPATHIC PULMONARY FIBROSIS Management of idiopathic pulmonary fibrosis: selected case reports Michael Kreuter 1, Peter Kardos 2 and Victor Hoffstein 3 Affiliations: 1 Dept of Pneumology
Epidemiology and classification of smoking related interstitial lung diseases
Epidemiology and classification of smoking related interstitial lung diseases Šterclová M. Department of Respiratory Diseases, Thomayer Hospital, Prague, Czech Republic Supported by an IGA Grant No G 1207
PULMONARY MEDICINE BOARD REVIEW. Financial Conflicts of Interest. Question #1: Question #1 (Cont.): None. Christopher H. Fanta, M.D.
PULMONARY MEDICINE BOARD REVIEW Christopher H. Fanta, M.D. Pulmonary and Critical Care Division Brigham and Women s Hospital Partners Asthma Center Harvard Medical School Financial Conflicts of Interest
Multidisciplinary Diagnosis in Action: Challenging Case Presentations
Multidisciplinary Diagnosis in Action: Challenging Case Presentations Interstitial Lung Disease: Advances in Diagnosis and Management UCSF CME November 8, 2014 Case 1 69 yo M 3 year history of intermittent
Challenges in Pulmonary and Critical Care 2017
Challenges in Pulmonary and Critical Care 2017 Idiopathic Pulmonary Fibrosis: New Advances in Therapy Outcome Report: Boehringer Ingelheim Grant # ME201722329 February 2, 2018 Level 1 (Participation) Practice
Radiologic Approach to Smoking Related Interstitial Lung Disease
Radiologic Approach to Smoking Related Interstitial Lung Disease Poster No.: C-1854 Congress: ECR 2013 Type: Educational Exhibit Authors: K.-N. Lee, J.-Y. Han, E.-J. Kang, J. Kang; Busan/KR Keywords: Toxicity,
ARTICLE IN PRESS. Ahuva Grubstein a, Daniele Bendayan b, Ithak Schactman c, Maya Cohen a, David Shitrit b, Mordechai R. Kramer b,
Respiratory Medicine (2005) 99, 948 954 Concomitant upper-lobe bullous emphysema, lower-lobe interstitial fibrosis and pulmonary hypertension in heavy smokers: report of eight cases and review of the literature
Regulatory Status FDA-approved indication: Ofev is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF) (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.05 Subject: Ofev Page: 1 of 5 Last Review Date: March 17, 2017 Ofev Description Ofev (nintedanib)
Disclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:
Disclosures Pharmacological Therapy for ILD What to Use and How to Use It Harold R Collard MD Interstitial Lung Disease Program University of California San Francisco (UCSF) I have relationships with the
Pulmonary Test Brenda Shinar
Pulmonary Test 2016 Brenda Shinar 1. What is a Renal Tubular Acidosis? What is the difference between the types of RTAs in terms of who gets them and how to diagnose them? Type 1, 2, and 4? Metabolic acidosis
NONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP
UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF () FOR PATHOLOGISTS Thomas V. Colby, M.D. Professor of Pathology (Emeritus) Mayo Clinic Arizona FINANCIAL DISCLOSURES NONE OVERVIEW IPF Radiologic Dx Pathologic
Strategies for Updated Treatment Options for IPF
Strategies for Updated Treatment Options for IPF Paul W. Noble, MD Vera and Paul Guerin Family Distinguished Chair in Pulmonary Medicine Professor and Chair Department of Medicine Director, Women's Guild
Current Management of IPF and. Dr R Lakshmi Narasimhan Dept of Pulmonary Medicine
Current Management of IPF and fibrosing ILDs Dr R Lakshmi Narasimhan Dept of Pulmonary Medicine Introduction Idiopathic pulmonary fibrosis clinical course is variable and long term survival is poor Therapy
Lung Allograft Dysfunction
Lung Allograft Dysfunction Carlos S. Restrepo M.D. Ameya Baxi M.D. Department of Radiology University of Texas Health San Antonio Disclaimer: We do not have any conflict of interest or financial gain to
Interstitial Pneumonia Related to Undifferentiated Connective Tissue Disease Pathologic Pattern and Prognosis
[ Original Research Diffuse Lung Disease ] Interstitial Pneumonia Related to Undifferentiated Connective Tissue Disease Pathologic Pattern and Prognosis Ho-Cheol Kim, MD ; Wonjun Ji, MD ; Mi Young Kim,
Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis
Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis Brad Zimmermann, PharmD, MBA Pharmacy Grand Rounds May 02, 2017 Rochester, Minnesota 2017 MFMER slide-1 Objectives
Ó Journal of Krishna Institute of Medical Sciences University 99
ISSN 2231-4261 CASE REPORT Dyskeratosis Congenita Associated Non-Specific Interstitial Pneumonia 1 1* Unnati D. Desai, Jyotsna M. Joshi 1 Department of Pulmonary Medicine, TNMC & BYL Nair Hospital, AL
ILD and systemic disease
Department for Pulmonology, University Hospital Berne ILD and systemic disease Dr. med. Manuela Funke-Chambour Oberärztin I Female patient, born 1945 Portuguese Presented with cough and dyspnea, no other
USEFULNESS OF HRCT IN DIAGNOSIS AND FOLLOW UP OF PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS
USEFULNESS OF HRCT IN DIAGNOSIS AND FOLLOW UP OF PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS Brestas P., Vergadis V., Emmanouil E., Malagari K. 2 nd Dept of Radiology, University of Athens, Greece ABSTRACT
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Hunninghake GM, Hatabu H, Okajima Y, et al. MUC5B promoter
Controversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF)
Controversies in Clinical Trials Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF) Controversies to be highlighted by IPF Post-hoc analyses Story Primary end point selection Changing prespecified endpoints
Eastern Mediterranean Health Journal, Vol. 14, No. 5,
Eastern Mediterranean Health Journal, Vol. 14, No. 5, 2008 1217 Case report Inappropriate use of steroid and Pneumocystis jiroveci pneumonia: report of two cases P. Tabarsi, 1 M. Mirsaeidi, 1 M. Amiri,